<?xml version="1.0" encoding="UTF-8"?>
<!--REG30PARAB V1.0 (01-06-2026)-->
<xbrli:xbrl xmlns:in-capmkt="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt" xmlns:in-capmkt-ent="http://www.sebi.gov.in/xbrl/Regulation_30_Para_B_Of_Part_A_Of_Schedule_III/2026-04-30/in-capmkt/in-capmkt-ent" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-types="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.w3.org/1999/xlink"><link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2026-04-30.xsd"/><xbrli:context id="MainI"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">533164</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-09-30</xbrli:instant></xbrli:period></xbrli:context><in-capmkt:NSESymbol contextRef="MainI">TEXMOPIPES</in-capmkt:NSESymbol><in-capmkt:NameOfTheCompany contextRef="MainI">Texmo Pipes and Products Limited</in-capmkt:NameOfTheCompany><in-capmkt:ScripCode contextRef="MainI">533164</in-capmkt:ScripCode><in-capmkt:MSEISymbol contextRef="MainI">NOTLISTED</in-capmkt:MSEISymbol><in-capmkt:ISIN contextRef="MainI">INE141K01013</in-capmkt:ISIN><in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">Key licenses or regulatory approvals (Sub-para 12-Para B)</in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">New</in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting contextRef="MainI">false</in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting><in-capmkt:DateOfOccurrenceOfEventOrInformation contextRef="MainI">2026-09-29</in-capmkt:DateOfOccurrenceOfEventOrInformation><in-capmkt:TimeOfOccurrenceOfEventOrInformation contextRef="MainI">17:45:00</in-capmkt:TimeOfOccurrenceOfEventOrInformation><in-capmkt:DateOfReport contextRef="MainI">2026-09-30</in-capmkt:DateOfReport><in-capmkt:EventTypeOfKeyLicenseOrRegulatoryApproval contextRef="MainI">Regulatory approvals</in-capmkt:EventTypeOfKeyLicenseOrRegulatoryApproval><in-capmkt:StageOfDisclosureOfKeyLicenseOrRegulatoryApproval contextRef="MainI">Granting</in-capmkt:StageOfDisclosureOfKeyLicenseOrRegulatoryApproval><in-capmkt:NameOfRegulatoryOrLicensingAuthority contextRef="MainI">National Stoxk Exchange of India Limited and BSE Limited</in-capmkt:NameOfRegulatoryOrLicensingAuthority><in-capmkt:BriefDetailsOfApprovalOrLicenseObtainedOrWithdrawnOrSurrendered contextRef="MainI">The Company has received In-Principle Approval from NSE and BSE under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for the proposed preferential issue and allotment of up to 15,30,000 (Fifteen Lakh Thirty Thousand) Equity Shares of the Company to the proposed allottees, subject to compliance with the applicable laws, regulations and conditions stipulated in the approval letters.</in-capmkt:BriefDetailsOfApprovalOrLicenseObtainedOrWithdrawnOrSurrendered><in-capmkt:ImpactOrRelevanceOfApprovalOrLicenseToListedEntity contextRef="MainI">Receipt of the In-Principle Approvals enables the Company to proceed with the preferential issue and allotment of equity shares, subject to fulfilment of the conditions specified in the approval letters and compliance with applicable statutory and regulatory requirements. The proceeds from the preferential issue shall be utilized for the purposes as approved by the shareholders and disclosed in the explanatory statement to the notice convening the general meeting.</in-capmkt:ImpactOrRelevanceOfApprovalOrLicenseToListedEntity><in-capmkt:ReasonsForActionOfGrantingOrWithdrawalOrSurrenderOrCancellationOrSuspensionOfKeyLicensesOrRegulatoryApprovals contextRef="MainI">Receipt of the In-Principle Approvals enables the Company to proceed with the preferential issue and allotment of equity shares, subject to fulfilment of the conditions specified in the approval letters and compliance with applicable statutory and regulatory requirements. The proceeds from the preferential issue shall be utilized for the purposes as approved by the shareholders and disclosed in the explanatory statement to the notice convening the general meeting.</in-capmkt:ReasonsForActionOfGrantingOrWithdrawalOrSurrenderOrCancellationOrSuspensionOfKeyLicensesOrRegulatoryApprovals><in-capmkt:EstimatedImpactOfKeyLicenseOrRegulatoryApprovalOnListedEntity contextRef="MainI">Not applicable</in-capmkt:EstimatedImpactOfKeyLicenseOrRegulatoryApprovalOnListedEntity><in-capmkt:PenaltyRelatedToKeyLicenseOrRegulatoryApproval contextRef="MainI">Not applicable</in-capmkt:PenaltyRelatedToKeyLicenseOrRegulatoryApproval><in-capmkt:PeriodOfKeyLicenseOrRegulatoryApproval contextRef="MainI">The approvals shall remain valid for the preferential issue and allotment of equity shares, subject to the terms, conditions and validity period specified in the respective approval letters issued by NSE and BSE and compliance with applicable laws.</in-capmkt:PeriodOfKeyLicenseOrRegulatoryApproval><in-capmkt:ActualImpactOfKeyLicenseOrRegulatoryApprovalOnListedEntity contextRef="MainI">Not applicable</in-capmkt:ActualImpactOfKeyLicenseOrRegulatoryApprovalOnListedEntity><in-capmkt:CorrectiveActionsTakenByTheListedEntityPursuantToTheWithdrawalOrSurrenderOrCancellationOrSuspensionOfKeyLicensesOrRegulatoryApprovals contextRef="MainI">Not applicable</in-capmkt:CorrectiveActionsTakenByTheListedEntityPursuantToTheWithdrawalOrSurrenderOrCancellationOrSuspensionOfKeyLicensesOrRegulatoryApprovals></xbrli:xbrl>
